GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang Ausun Pharmaceutical Co Ltd (SHSE:603229) » Definitions » Total Assets

Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Total Assets : ¥3,017.6 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Ausun Pharmaceutical Co Total Assets?

Zhejiang Ausun Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2024 was ¥3,017.6 Mil.

Warning Sign:

If a company builds assets at 35.8% a year, faster than its revenue growth rate of 26.8% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Zhejiang Ausun Pharmaceutical Co's average Total Assets Growth Rate was 2.50% per year. During the past 3 years, the average Total Assets Growth Rate was 41.70% per year. During the past 5 years, the average Total Assets Growth Rate was 35.80% per year. During the past 10 years, the average Total Assets Growth Rate was 25.00% per year.

During the past 12 years, Zhejiang Ausun Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 46.30%. The lowest was 8.60%. And the median was 25.90%.

Total Assets is connected with ROA %. Zhejiang Ausun Pharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2024 was 6.56%. Total Assets is also linked to Revenue through Asset Turnover. Zhejiang Ausun Pharmaceutical Co's Asset Turnover for the quarter that ended in Sep. 2024 was 0.07.


Zhejiang Ausun Pharmaceutical Co Total Assets Historical Data

The historical data trend for Zhejiang Ausun Pharmaceutical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Ausun Pharmaceutical Co Total Assets Chart

Zhejiang Ausun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 886.15 1,381.69 1,839.46 2,315.33 2,951.57

Zhejiang Ausun Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,973.29 2,951.57 3,045.06 2,980.63 3,017.62

Zhejiang Ausun Pharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Zhejiang Ausun Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=2141.577+809.995
=2,951.6

Zhejiang Ausun Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=2294.064+723.56
=3,017.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Ausun Pharmaceutical Co  (SHSE:603229) Total Assets Explanation

Total Assets is connected with ROA %.

Zhejiang Ausun Pharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=196.612/( (2980.633+3017.624)/ 2 )
=196.612/2999.1285
=6.56 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Zhejiang Ausun Pharmaceutical Co's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=197.733/( (2980.633+3017.624)/ 2 )
=197.733/2999.1285
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Zhejiang Ausun Pharmaceutical Co Total Assets Related Terms

Thank you for viewing the detailed overview of Zhejiang Ausun Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Ausun Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.5, Donghai 4th Avenue, chemical raw materials base Linhai Park East, Zhejiang Province, Taizhou, CHN, 317016
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
Executives
Zheng Zhi Guo Directors, senior managers
Zhang Hua Dong Directors, senior managers
Liu Bing Director

Zhejiang Ausun Pharmaceutical Co Headlines

No Headlines